<?xml version="1.0" encoding="UTF-8"?><abstracts-retrieval-response xmlns="http://www.elsevier.com/xml/svapi/abstract/dtd" xmlns:ait="http://www.elsevier.com/xml/ani/ait" xmlns:ce="http://www.elsevier.com/xml/ani/common" xmlns:cto="http://www.elsevier.com/xml/cto/dtd" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:prism="http://prismstandard.org/namespaces/basic/2.0/" xmlns:xocs="http://www.elsevier.com/xml/xocs/dtd" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><coredata><prism:url>http://api.elsevier.com/content/abstract/scopus_id/84907260610</prism:url><dc:identifier>SCOPUS_ID:84907260610</dc:identifier><eid>2-s2.0-84907260610</eid><prism:doi>10.1016/j.copbio.2014.08.001</prism:doi><dc:title>Protein aggregation and its impact on product quality</dc:title><prism:aggregationType>Journal</prism:aggregationType><srctype>j</srctype><citedby-count>1</citedby-count><prism:publicationName>Current Opinion in Biotechnology</prism:publicationName><dc:publisher>
Elsevier Ltd
</dc:publisher><source-id>15579</source-id><prism:issn>18790429</prism:issn><prism:volume>30</prism:volume><prism:startingPage>211</prism:startingPage><prism:endingPage>217</prism:endingPage><prism:pageRange>211-217</prism:pageRange><prism:coverDate>2014-01-01</prism:coverDate><dc:creator><author auid="7404402457" seq="1"><ce:initials>C.J.</ce:initials><ce:indexed-name>Roberts C.J.</ce:indexed-name><ce:surname>Roberts</ce:surname><ce:given-name>Christopher J.</ce:given-name><preferred-name>
<ce:initials>C.J.</ce:initials>
<ce:indexed-name>Roberts C.</ce:indexed-name>
<ce:surname>Roberts</ce:surname>
<ce:given-name>Christopher J.</ce:given-name>
</preferred-name><author-url>http://api.elsevier.com/content/author/author_id/7404402457</author-url></author></dc:creator><dc:description><abstract original="y" xml:lang="eng">
<ce:para>Protein pharmaceutical products are typically active as folded monomers that are composed of one or more protein chains, such as the heavy and light chains in monoclonal antibodies that are a mainstay of current drug pipelines. There are numerous possible aggregated states for a given protein, some of which are potentially useful, while most of which are considered deleterious from the perspective of pharmaceutical product quality and performance. This review provides an overview of how and why different aggregated states of proteins occur, how this potentially impacts product quality and performance, fundamental approaches to control aggregate formation, and the practical approaches that are currently used in the pharmaceutical industry. Â© 2014 Elsevier Ltd.</ce:para>
</abstract></dc:description><link href="http://api.elsevier.com/content/abstract/scopus_id/84907260610" rel="self"/><link href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84907260610&amp;origin=inward" rel="scopus"/><link href="http://api.elsevier.com/content/search/scopus?query=refeid%282-s2.0-84907260610%29" rel="cited-by"/></coredata><authors><author auid="7404402457" seq="1"><ce:initials>C.J.</ce:initials><ce:indexed-name>Roberts C.J.</ce:indexed-name><ce:surname>Roberts</ce:surname><ce:given-name>Christopher J.</ce:given-name><preferred-name>
<ce:initials>C.J.</ce:initials>
<ce:indexed-name>Roberts C.</ce:indexed-name>
<ce:surname>Roberts</ce:surname>
<ce:given-name>Christopher J.</ce:given-name>
</preferred-name><author-url>http://api.elsevier.com/content/author/author_id/7404402457</author-url></author></authors></abstracts-retrieval-response>
